A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes.

Pardo-Seco, Jacobo; Rodriguez-Tenreiro-Sánchez, Carmen; Giné-Vázquez, Iago; Mallah, Narmeen; Mirás-Carballal, Susana; Piñeiro-Sotelo, Marta; Cribeiro González, Martín; Conde Pájaro, Mónica et al. · Clin Infect Dis · 2026

rct · Level II

Where this comes from

Record sourced from PubMed, PMID 42546169.
Also identified by DOI 10.1093/cid/ciag466.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

The GALFLU trial showed a lower incidence of hospitalisation among adults aged 65-79 years randomised to high-dose inactivated influenza vaccine (HD-IIV) compared with standard-dose inactivated influenza vaccine (SD-IIV). This Bayesian re-analysis estimated an >80% probability of benefit (rVE >10%) against influenza-or-pneumonia-related hospitalisation, supporting the benefit of HD-IIV over SD-IIV.

Read the full text

View on PubMed · Publisher (DOI)